...diseases. Stockwell is a professor at Columbia University and co-founder of Kyras Therapeutics Inc. and CombinatoRx Inc....

...Horizon said its CombinatoRx division received a contract from Otsuka to perform in vitro cell line...
...completed” this year. The company declined to comment on specific research plans, but said the CombinatoRx...
...help to guide development efforts.” Otsuka declined to comment on the deal. Horizon acquired its CombinatoRx...

...Horizon completed its acquisition of Zalicus' CombinatoRx combination high throughput screening (cHTS) business and related assets...
...for $8 million. The business will become a subsidiary of Horizon and be named Horizon CombinatoRx Inc....

...Horizon will acquire Zalicus' CombinatoRx combination high throughput screening (cHTS) business and related assets for $8...
...$8 million. The business will become a subsidiary of Horizon and will be named Horizon CombinatoRx Inc....

...depending on Zalicus' net cash when the deal closes. At Dec. 31, 2013, Zalicus (formerly CombinatoRx Inc....

...depending on Zalicus' net cash when the deal closes. At Dec. 31, 2013, Zalicus (formerly CombinatoRx Inc....

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....

...did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd. , which merged with CombinatoRx Inc....